Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult for patients because of a lack of awareness and investment in supporting people with the condition.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
